Type of clinical trial
Category
Study Ended
Study phase (clinical trials only)
multi- / monocentric
BASEC ID Project title Type of project Type of clinical trial Study phase (clinical trials only) multi- / monocentric Category Principal investigator Sponsor Investigational sites Lead EC Local EC(s) Approval date Minors Study Ended
2021-02153 Appropriateness of in-hospital intravenous iron therapy in a Swiss tertiary care hospital – a quality control study personal data/biological material monocentric PD Dr. med. Michael Osthoff Universitätsspital Basel Universitätsspital Basel, Basel
Ethikkommission Nordwest- und Zentralschweiz EKNZ 18.11.2021
2021-02025 Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of acute ischemic cerebral and renal events after transcatheter aortic valve implantation: a single-center, randomized, double More ... clinical trial drugs phase 2 monocentric C PD Dr. med. Michael Osthoff Innere Medizin University Hospital Basel, Basel
Ethikkommission Nordwest- und Zentralschweiz EKNZ 30.11.2021
2021-01338 Occurrence of antibodies cross-reacting with autoantigens in primary EBV infection – a longitudinal, observational study non clinical, involving persons monocentric A PD Dr. med. Michael Osthoff University Hospital Basel, Division of Internal Medicine University Hospital Basel, Basel
Ethikkommission Nordwest- und Zentralschweiz EKNZ 17.08.2021
2021-00379 Probability of early target attainment with continuously administered piperacillin/tazobactam and meropenem in critically ill patients: A retrospective cohort study from 2017 to 2021 personal data/biological material monocentric PD Dr. Michael Osthoff University Hospital Basel, Basel
Ethikkommission Nordwest- und Zentralschweiz EKNZ 24.02.2021
2021-00201 Evaluation of the FilmArray meningitis/encephalitis panel at the University Hospital Basel: a retrospective study personal data/biological material monocentric PD Dr. med. Michael Osthoff University Hospital Basel, Basel
Ethikkommission Nordwest- und Zentralschweiz EKNZ 03.02.2021
2020-02260 A novel rapid, mobile, lab-independent and sensitive SARS-CoV-2 test at the point-of-need, to break the chain of infection non clinical, involving persons monocentric A PD Dr. Michael Osthoff University Hospital Basel, Basel
Ethikkommission Nordwest- und Zentralschweiz EKNZ 16.04.2021
2020-01252 Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: a randomized, parallel-group, open-label, multi-center More ... clinical trial drugs phase 2 multicentric C PD Dr. med. Michael Osthoff University Hospital Basel University Hospital Basel, Basel
Kantonsspital St. Gallen, St. Gallen
Klinik für Innere Medizin, Stadtspital Triemli Zürich, Zürich
Ethikkommission Nordwest- und Zentralschweiz EKNZ Ethikkommission Ostschweiz (EKOS), Kantonale Ethikkommission Zürich 07.07.2020 Study has ended
2020-01013 Compassionate use of recombinant human C1 esterase inhibitor (Conestat alfa) in the prevention of clinical deterioration in high-risk subjects with COVID-19 pneumonia: a case series and matched case-c More ... personal data/biological material monocentric PD Dr. med. Michael Osthoff University Hospital Basel University Hospital Basel, Basel
Ethikkommission Nordwest- und Zentralschweiz EKNZ 04.05.2020
2019-02229 Probability of target attainment with standard intermittent bolus administration of cefazolin in patients with complicated infections caused by Staphylococcus aureus: A prospective single-center cohor More ... non clinical, involving persons monocentric A PD Dr. med. Michael Osthoff University Hospital Basel University Hospital Basel, Basel
Ethikkommission Nordwest- und Zentralschweiz EKNZ 20.12.2019
2019-01716 Conestat alfa ( a recombinant human C1 esterase inhibitor) for the prevention of acute kidney injury after non - ST elevation myocardial infarction: a randomized, double-blind, placebo control, multi More ... clinical trial drugs phase 2 multicentric C PD Dr. med. Michael Osthoff Pharming Technologies B.V. University Hospital Basel, Basel
Inselspital Bern, Bern
Hôpitaux Unversitaires Geneve (HUG), Genève
Fondazione Cardiocentro Ticino, Lugano
Ethikkommission Nordwest- und Zentralschweiz EKNZ Kantonale Ethikkommission Bern, Commission Cantonale d'éthique de la recherche Genève (CCER), Comitato etico cantonale Ticino 28.10.2019
2019-00185 Evaluation of the Duration of Antimicrobial Treatments in Common Infectious Diseases at Three Swiss Tertiary Care Hospitals – a Quality Control Study personal data/biological material multicentric PD Dr. med. Michael Osthoff Universitätsspital Basel Universitätsspital Basel, Basel
Kantonsspital Aarau, Aarau
Kantonsspital St. Gallen, St. Gallen
Ethikkommission Nordwest- und Zentralschweiz EKNZ Ethikkommission Nordwest- und Zentralschweiz EKNZ, Ethikkommission Ostschweiz (EKOS) 06.02.2019
2019-00012 Recombinant human C1 esterase inhibitor (Conestat alfa) in the prevention of contrast-induced nephropathy in high-risk subjects (PROTECT): a randomized, placebo-controlled, double-blind single-center More ... personal data/biological material monocentric PD Dr. med. Michael Osthoff Universitätsspital Basel, Klinik Innere Medizin Universitätsspital Basel, Basel
Ethikkommission Nordwest- und Zentralschweiz EKNZ 11.01.2019
2017-02072 Probability of target attainment with standard intermittent bolus administration of β-lactam antibiotics in patients with bloodstream infections caused by Staphylococcus aureus and aerobic Gram-negati More ... non clinical, involving persons monocentric A PD Dr. med. Michael Osthoff Universitätsspital Basel University Hospital Basel, Basel
Ethikkommission Nordwest- und Zentralschweiz EKNZ 21.12.2017 Study has ended
2017-00539 Comprehensive analysis of the Outpatient Parenteral Antibiotic Therapy (OPAT) program at the University Hospital Basel during 2015-2016 personal data/biological material monocentric PD Dr. med. Michael Osthoff Universitätsspital Basel, Klinik Innere Medizin, Basel
Ethikkommission Nordwest- und Zentralschweiz EKNZ 09.05.2017
2016-01112 Recombinant human C1 esterase inhibitor (Conestat alfa) in the prevention of contrast-induced nephropathy in high-risk subjects (PROTECT): a randomized, placebo-controlled, double-blind single-center More ... clinical trial drugs phase 2 monocentric C Dr. med. Michael Osthoff Universitätsspital Basel, Klinik für Innere Medizin Universitätsspital Basel, Department Infektiologie und Spitalhygiene, Basel
Ethikkommission Nordwest- und Zentralschweiz EKNZ 25.08.2016 Study has ended